AHN-12 Biodistribution in Advanced Leukemia

Key facts

Sponsor

Masonic Cancer Center, University of Minnesota

Principal Investigator

Linda Burns, M.D., MD

Masonic Cancer Center, University of Minnesota

Intervention

90Y-AHN-12(biological)

Enrollment

8 target

Eligibility

12 years · All sexes

Timeline

2013 – 2014

Study locations (1)

• Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Myelodysplastic/myeloproliferative disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT05564390
  MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT06532084
  Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen
  St. Petersburg State Pavlov Medical University
• RECRUITINGPHASE2NCT05788679
  A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
  Karolinska University Hospital
• RECRUITINGPHASE2NCT04493164
  CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
  M.D. Anderson Cancer Center

See all trials for Myelodysplastic/myeloproliferative disease →